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The extracellular matrix is an important structure in maintenance
of tissue organization and in the suppression of cellular prolifera-
tion and migration. Excess destruction of the extracellular matrix
is associated with many pathologies including atherosclerosis,
rheumatoid arthritis and cancer progression. The intricate balance
between net extracellular matrix deposition and degradation is
controlled by a complex system of tightly regulated protease
enzymes and their endogenous inhibitors. Matrix destruction is
thought to be a key event in both the local invasion and distant
metastasis associated with tumour progression and genes that
inhibit these processes may be useful for cancer therapy.
The matrix degrading metalloproteinases (MMPs) are a large
family of enzymes that together can degrade all components of the
extracellular matrix (Birkedal-Hansen et al, 1993). Within the
extracellular matrix, the tissue inhibitor of metalloproteinases
(TIMPs), of which there are four family members (Docherty et al,
1985; Stetler-Stevenson et al, 1990; Uría et al, 1994; Leco et al,
1997), inhibit the activity of MMPs by binding with a 1:1
stoichiometry to the active site (Bode et al, 1994). Proteolytic
processing of pro-MMP-9 to its active form is also inhibited by
additional binding of TIMP-1 at the C-terminal site, while TIMP-2
plays a more complex biphasic role in the activation of MMP-2
(Murphy et al, 1992; Strongin et al, 1995). A number of studies
have indicated the potential use of overexpression of TIMP genes
for cancer therapy using plasmid, and retrovirus-based gene
transfer systems (DeClerck et al, 1992; Imren et al, 1992;
Montgomery et al, 1994; Watanabe et al, 1996; Smith et al, 1997;
Wang et al, 1997), or by using synthetic MMP inhibitors (Koop et
al, 1994; Wang et al, 1994; Sledge et al, 1995; Low et al, 1996;
Watson et al, 1996).
Unlike TIMP-1, -2 and -4, TIMP-3 is sequestered into the extra-
cellular matrix (Leco et al, 1994) although the precise binding
site(s) for TIMP-3 are not yet known. High levels of TIMP-3 are
expressed in cartilage, epithelia, muscle and in invading cyto-
trophoblasts (Apte et al, 1994; Bass et al, 1997) and have been
detected in breast carcinoma (Uría et al, 1994) localized to the
stroma (Byrne et al, 1995). Our previous studies have shown that
overexpression of TIMP-3 in vascular smooth muscle cells and
melanoma cell lines inhibits invasion and promotes apoptotic cell
death (Ahonen et al, 1998; Baker et al, 1998). To investigate the
potential use of TIMP-3 for gene therapy of cancer of different
cell types, we have used a replication-defective recombinant-
adenovirus capable of overexpressing TIMP-3 (Baker et al, 1998).
We have assessed phenotypic changes associated with TIMP-3
overexpression on non-invasive MCF-7 adenocarcinoma cells
(Noel et al, 1991), moderately invasive HeLa cervical carcinoma
cells (Nuovo, 1997) and highly invasive HT1080 fibrosarcoma
cells (Noel et al, 1991) following adenoviral infection in vitro.
MATERIALS AND METHODS
Materials
All chemical reagents were obtained from Sigma (Poole, Dorset,
UK) unless otherwise stated. Cell culture reagents were obtained
from Gibco/BRL (Paisley, UK). P231 (aka BB-94) was a generous
gift from Pfizer (Sandwich, Kent, UK). The replication-defective
recombinant adenoviruses RAd35 (expresses lacZ from the CMV
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polyadenylation signal), RAdTIMP-1, -2 and -3 (express TIMP-1,
-2, or -3 from the CMV IEP, respectively) have been described in
detail elsewhere (Wilkinson and Akrigg, 1992; Baker et al, 1996,
1998). Stocks of adenovirus were purified on caesium chloride
gradients and assessed for lack of replication competent adeno-
virus by titration on non-permissive HeLa cells.
METHODS
Cell culture
HeLa, MCF-7 and HT1080 cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) containing 10% fetal calf
serum (FCS), 100 mg/ ml–1 penicillin and 100 units per ml strepto-
mycin (complete media) unless otherwise stated and maintained in
a humidified atmosphere at 37°C in 5% carbon dioxide. For
assays, 1 ´ 105 cells were plated in 6-well plates 24 h prior to
infection (for certain experiments, cells were plated in a similar
manner but onto glass coverslips). One set of triplicate wells were
counted for an accurate calculation of cell number immediately
prior to infection. Cells were incubated with recombinant adeno-
viruses in 2 ml of fresh complete media and left for 18 h. Cells
were then washed and further incubated in fresh complete media
until the required time point.
Quantification of adenoviral infection efficiency
Cells were either mock infected or infected with RAd35 at
increasing multiplicities of infection (MOI) for 18 h, washed and
incubated for a further 24 h in complete media. Cells were stained
with X-gal stain (5-bromo-4-chloro-3-indoyl-b-D-galactopyrano-
sidase) [100 mM sodium phosphate pH 7.3 (77 mM Na2HPO4,
23 mM NaH2PO4), 1.3 mM MgCl2, 3 mM K3Fe(CN)6, 3 mM
K4Fe(CN)6 and 1 mg ml–1 X-gal] and counterstained with nuclear
fast red. Positive (blue cells) were counted in four high power
fields per section from triplicate cultures and the percentage infec-
tion efficiency calculated.
Analysis of transgene production
HeLa cells were used for analysis of TIMP-3 overexpression.
Briefly, cells were infected for 18 h in complete media, washed
and further incubated in media containing 2% FCS for 24 h. For
all infections, the conditioned media (2 ml) were collected and
stored at –20°C prior to analysis. As TIMP-3 is associated with the
extracellular matrix (Leco et al, 1994), the cell and extracellular
matrix fraction was harvested from uninfected, RAd66 and
RAdTIMP-3 infected cells as described elsewhere (Baker et al,
1998). Conditioned media were concentrated tenfold using
Centricon microconcentrators (Amicon Inc., Stonehouse, UK). All
samples were electrophoresed on 11% polyacrylamide gels and
membranes were probed with a mouse anti-human TIMP-3 (a
generous gift from K Iwata, Fuji Chemicals Ltd, Japan). Bands
were visualized using enhanced chemiluminescence (ECL,
Amersham International, UK).
Matrigel invasion assay
Infected and uninfected HeLa and HT1080 cells were analysed for
their invasive capacity across artificial basement membrane using
modified Boyden chambers (Nucleopore, Middlesex, UK).
Briefly, 2 ´ 104 HeLa cells (or 5 ´ 103 HT1080 cells) in DMEM
without phenol red containing 1% bovine serum albumin (BSA)
were placed in the upper chamber with a 0.4 mg/mm2 Matrigel
barrier (Stratech, Luton, UK). Media containing 10% FCS as a
chemoattractant were placed in the lower chamber and invasion
allowed to commence for 24 h. Uninfected cells were also incu-
bated with BB-94 to compare TIMP-3 effects with those of a
synthetic MMP inhibitor. Cells that had invaded the basement
membrane were fixed in methanol, stained with haematoxylin and
cells on the lower surface of the filter counted (4 ´ 200 fields per
section).
Analysis of cell number
At the required time point, viable adherent cells from triplicate
cultures were counted using a haemacytometer and trypan blue
exclusion.
Terminal dUTP nick end labelling (TUNEL) analysis of
cell death by apoptosis
Following fixation in methanol, HeLa cells were washed in 1 ´ TE
(10 mM Tris-HCl, 1 mM EDTA, pH 8.0) and labelled in buffer
containing 100 mM cacodylate (pH 6.4), 1 mM CoCl2, 1 mM
dithothreitol, 0.01 mM biotin-dUTP and 8 units per ml terminal
deoxynucleotidyl transferase (Promega, Southampton, UK) at
37°C for 60 min. Cells were washed, and biotin-dUTP labelled
nuclei were detected using streptavidin–peroxidase and diamino-
benzidine staining.
Evaluation of bromodeoxyuridine (BrdU) incorporation
Cells were pulsed with 10 mM BrdU for 1 h prior to fixation. Cells
were stained using a mouse monoclonal anti-BrdU antibody and
immunocytochemical detection. Cells were counted in four high-
powered fields per section from triplicate cultures.
Flow cytometric analysis of apoptosis and cell cycle
parameters
Cells were trypsinized at the required time point, washed, resus-
pended in phosphate-buffered saline (PBS) and fixed in 70%
ethanol in PBS. Prior to analysis, cells were resuspended in 400 ml
of PBS, and 50 ml of 400 mg ml–1 propidium iodine and 50 ml of
100 mg ml–1 RNaseA were added and left at room temperature for
30 min. Cells were analysed on a Becton-Dickinson FACScan
flow cytometer and data analysed using winMDI and Multicycle
software.
Statistical analysis
All data were analysed using an unpaired Student’s t-test and are
shown as the mean value ± s.e.m.
RESULTS
Adenoviral infection efficiency
In uninfected HeLa, HT1080 and MCF-7 cells, no b-galactosidase
positivity was observed (not shown). HeLa cells were efficiently
1348 AH Baker et al
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Figure 1 Analysis of recombinant TIMP-3 secretion. A total of 105 HeLa cells were infected with recombinant adenoviruses for 18 h, washed and maintained in
2% FCS-containing media for 24 h. Conditioned media (tenfold concentrated) and cell/matrix lysates were subsequently analysed for TIMP-3 by Western blot
analysis. 1, 2: uninfected control cells; 3–5: RAd66 30 pfu per cell; 6–8: RAd66 80 pfu per cell; 9–11: RAdTIMP-3 30 pfu per cell; 12–14: RAdTIMP-3 80 pfu per
cell. The small arrow represents the glycosylated form of TIMP-3 and the large arrow the unglycosylated form
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Figure 2 Effect of TIMP-3 on cancer cell invasion in vitro. Cells were infected with recombinant adenoviruses at 80 pfu per cell for HeLa and 300 pfu per cell
for HT1080 cells for 18 h. A total of 2 ´ 104 HeLa cells or 5 ´ 103 HT1080 cells were then analysed for invasion through reconstituted basement membrane
following overexpression of individual TIMPs. *Indicates statistical significance (P < 0.05, n = 12) vs uninfected and RAd66-infected controls1350 AH Baker et al
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Figure 3Effect of TIMP-3 overexpression on cancer cell growth. A total of 1 ´105 HeLa, HT1080 or MCF-7 cells were infected with RAd66 or RAdTIMP-3 and
cultured in complete media until 90h post infection (66h for HT1080 cells). Viable adherent cells were counted from triplicate cultures. 1: uninfected cells; 2 and
3: RAd66-infected cells (30 and 80pfu per cell for HeLa cells; 100 and 300pfu per cell for HT1080 cells; 200 and 600pfu per cell for MCF-7 cells, respectively);
4 and 5: RAdTIMP-3-infected cultures at same pfu per cell as (2) and (3), respectively; 6: BB-94. *Indicates statistical significance (P < 0.05 vs respective
RAd66 control, n = 3)
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Figure 4Morphological analysis of cultures. Phase contrast photographs of HeLa (A–C), HT1080 (D–F) and MCF-7 (G–I) cells at 66h post infection.
Uninfected (A, D, G), RAd66 control adenovirus-infected (B, 80pfu per cell; E, 300pfu per cell; H, 600pfu per cell) and RAdTIMP-3-infected (C, 80pfu per cell;
F, 300pfu per cell; I, 600pfu per cell) cells are shown. The scale bar in Arepresent 50mm and is applicable to all panelsand dose-dependently infected with RAd35 as assessed by staining
for b-galactosidase. Infection with 30 and 80 pfu per cell resulted
in 35 ± 1% and 70 ± 1% infection, respectively. Higher MOIs were
required for high level infection of HT1080 and MCF-7 cells
(HT1080 cells: 100 pfu per cell 62 ± 3%, 300 pfu per cell 94 ± 2%;
MCF-7 cells: 200 pfu per cell 35 ± 2%, 600 pfu per cell 66 ± 4%).
Analysis of transgene production
Uninfected HeLa cells showed very low level production of
TIMP-3 both in the cell/matrix fraction and in the conditioned
media (Figure 1). RAd66 infection at 30 or 80 pfu per cell had no
effect on TIMP-3 secretion per se (Figure 1). For RAdTIMP-3-
infected cells, high level transgene production was observed both
in the cell/matrix fraction and in the conditioned media consistent
with previous observations (Figure 1; Baker et al, 1998). Both the
unglycosylated and glycosylated form of TIMP-3 were detected
(Figure 1). Western blot analysis of uninfected and RAd66-
infected HT1080 and MCF-7 cell/matrix extracts failed to show
the presence of endogenous TIMP-3 but RAdTIMP-3 infection
evoked similar high level TIMP-3 production (not shown).
TIMP-3 overexpression inhibits cancer cell invasion
To ascertain the effect of high level overexpression of TIMP-3 on
invasion of cancer cells in vitro, modified Boyden chamber assays
TIMP-3 induces apoptosis in cancer cells 1351
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Figure 5 TUNEL analysis of cancer cells. HeLa (A and B, 80 pfu per cell), HT1080 (C and D, 300 pfu per cell) and MCF-7 cells (E and F, 600 pfu per cell)
were analysed 66 h post infection for TUNEL positivity as a marker of apoptosis following infection with RAd66 (A, C, E) or RAdTIMP-3 (B, D, F). Dark nuclei
represent TUNEL-positive cells (representative examples indicated by arrows in B, D and F). The scale bar in A represents 10 mm and is applicable to all panelswere performed on uninfected, RAd66- and RAdTIMP-3-infected
cells. Due to the non-invasive capacity of MCF-7 cells (Nuovo,
1997), the effect of TIMP-3 overexpression on MCF-7 cell inva-
sion was not analysed. For HeLa and HT1080 cells, infection with
RAd66 (at 80 and 300 pfu per cell, respectively) had no effect on
the invasion of either cell type compared to uninfected cells
(Figure 2). Overexpression of TIMP-3 significantly inhibited inva-
sion of HeLa and HT1080 cells through reconstituted basement
membrane compared to uninfected and RAd66-infected controls
(Figure 2). The effect of TIMP-3 was comparable to that observed
by TIMP-1, TIMP-2 and the synthetic MMP inhibitor BB-94
(Figure 2).
TIMP-3 overexpression induces a dose-dependent
reduction in cell number
Infection of HeLa, HT1080 and MCF-7 cells with RAd66 had no
significant effect on cell numbers at 90 h post infection (Figure 3).
In contrast, TIMP-3 overexpression resulted in a dose-dependent
reduction in cell number for each cell type (Figure 3). The effect of
TIMP-3 was not mimicked when uninfected cells were cultured
with BB-94 (Figure 3).
TIMP-3 stimulates cell cycle entry and apoptosis in
cancer cells
We previously demonstrated in vascular smooth muscle cells that
overexpression of TIMP-3 enhanced DNA synthesis and induced
apoptosis. Morphological analysis of HeLa, HT1080 and MCF-7
cultures postinfection revealed that TIMP-3 overexpression
resulted in changes associated with apoptotic cell death including
membrane blebbing, cell shrinkage and nuclear chromatin conden-
sation (Figure 4). No evidence of cell death was observed with
overexpression of TIMP-1 or -2 or by culture in the presence of
BB-94 (results not shown). To evaluate apoptosis in TIMP-3 over-
expressing cells further, TUNEL analysis was performed. While
infection of cells with RAd66 or treatment with BB-94 had no
significant effect on the number of TUNEL-positive cells (Figure
5, BB-94 not shown), RAdTIMP-3 infection resulted in high
levels of TUNEL positive cells in HeLa, HT1080 and MCF-7 cells
(Figure 5). In HeLa cells, TUNEL positivity increased from 2.7 ±
0.7% for uninfected controls, 3.1 ± 1.3% for RAd66-infected cells
and 2.58 ± 0.7% for BB-94-treated cultures to 33.5 ± 0.6% for
RAdTIMP-3-infected cells (P < 0.05 for RAdTIMP-3-infected
HeLa cells vs uninfected, RAd66- and BB-94-treated cultures,
1352 AH Baker et al
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Figure 6 Effect of TIMP-3 overexpression on BrdU incorporation. Uninfected and infected HeLa (80 pfu per cell) and HT1080 (300 pfu per cell) cells were
pulsed with 10 mM BrdU for 1 h at 42 h post infection and the percentage BrdU positivity determined immunocytochemically from triplicate cultures. *Indicates
statistical significance from the uninfected and RAd66 control adenovirus-infected culture (P < 0.05, n = 3).
Table 1 Quantification of cell cycle characteristics of uninfected and infected HeLa and HT1080 cells
Cell line Treatment G0/G S G2/M aPre-G0
HeLa Uninfected 55 ± 0.5 27 ± 0.3 18 ± 0.2 3 ± 0.2
RAd66 80 pfu per cell 51 ± 0.3 28 ± 0.3 20 ± 13   ± 1
RAdTIMP-3 80 pfu per cell 39 ± 1b 35 ± 0.3b 26 ± 1b 9 ± 1b
HT1080 Uninfected 51 ± 2 28 ± 1 23 ± 15   ± 2
RAd66 100 pfu per cell 53 ± 2 23 ± 2 25 ± 0.4 5 ± 1
RAd66 300 pfu per cell 51 ± 1 22 ± 1 26 ± 0.2 5 ± 1
RAdTIMP-3 100 pfu per cell 29 ± 3b 34 ± 2b 37 ± 1b 9 ± 1b
RAdTIMP-3 300 pfu per cell 15 ± 0.2b 47 ± 1b 38 ± 1b 12 ± 0.2b
Cells were fixed 66 h post infection and analysed by propidium iodide staining and flow cytometric analysis for cell
cycle populations following RAd66 and RAdTIMP-3 infection. aFor pre-G0 analysis, data are presented as the
percentage of the total gated cell population. For G0/G1, S and G2/M, data are calculated from the percentage of cells
in cycle (i.e. excluding cells in the pre-G0 region). bP < 0.05 for RAdTIMP-3- versus respective RAd66-infected control.n = 3). Similar levels of TUNEL positivity were observed in
HT1080 and MCF-7 cells (data not shown).
Induction of DNA synthesis by TIMP-3 was assessed in HeLa
and HT1080 cells by BrdU analysis. TIMP-3 overexpression
significantly elevated the number of cells in S phase compared to
uninfected, RAd66-infected cultures and BB-94-treated cells
(Figure 6, BB-94 data not shown).
To confirm deregulation of the cell cycle by TIMP-3, flow cyto-
metric cell cycle analysis on propidium iodide-stained cells, HeLa
and HT1080 cells was performed 42 h (HeLa) or 66 h (HT1080)
post infection (Table 1). TIMP-3 overexpression resulted in a
significant elevation in the number of cells in cycle, both in S and
the G2/M phases of the cell cycle with a corresponding reduction in
G0/G1 (Table 1). In addition, by flow cytometry, the percentage of
cells in pre-G0 (apoptotic) was significantly elevated in
RAdTIMP-3-infected cells compared to RAd66-infected controls
(Table 1).
To examine whether the induction of apoptosis was initiated
extracellularly, exogenous recombinant human TIMP-3 (rTIMP-3)
was added to uninfected cultures of HT1080 cells. Western blot
analysis revealed that exogenous TIMP-3 was associated with the
cell/matrix lysates (Figure 7A). In comparison to vehicle and
control protein-treated cultures, rTIMP-3 induced cell death
(Figure 7B, C).
DISCUSSION
The present study has documented the effect of overexpression of
TIMP-3 on the invasion, proliferation and death of cancer cells in
vitro. Efficient and high level TIMP-3 overexpression was demon-
strated in HeLa cells whereas control adenoviral infection had no
effect. Overexpression of TIMP-3 inhibited HeLa and HT1080 cell
invasion through reconstituted basement membrane, an effect
mimicked by overexpression of TIMP-1 and -2 and by a synthetic
TIMP-3 induces apoptosis in cancer cells 1353
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Figure 7 Effect of exogenous recombinant TIMP-3 on uninfected cancer cells. A total of 2 ´ 104 uninfected HT1080 cells were cultured in the presence of
vehicle, control protein (histone) or rTIMP-3. (A) Western blot analysis of cell/matrix lysates from cells 48 h post addition of histone or rTIMP-3 (both 2 mg). The
large arrow represents the unglycosylated form of TIMP-3 and the small arrow, the glycosylated form. (B) At 48 h post addition, viable adherent cells were
counted. 1: untreated control cells; 2: vehicle; 3 and 4: 0.5 and 2 mg histone, respectively; 5 and 6: 0.5 and 2 mg rTIMP-3, respectively. *Indicates statistical
significance vs untreated, vehicle and histone culture cells (P < 0.05, n = 3). (C) Phase contrast pictures of HT1080 cells at 48 h. 1: untreated cells; 2: histone
(2 mg); 3: rTIMP-3 (2 mg). The scale bar represents 100 mm and is applicable to all panels.MMP inhibitor. TIMP-3 also promoted cell cycle entry observed
by BrdU immunolabelling and by cell cycle analysis by flow
cytometry. Overexpression of TIMP-3 culminated in apoptotic cell
death of HeLa, HT1080 and MCF-7 cells assessed morphologi-
cally by flow cytometry and by TUNEL analysis. The effects on
DNA synthesis and death mediated by TIMP-3 were not repro-
duced by a synthetic MMP inhibitor.
The inhibition of cancer cell invasion by TIMP-3 overexpres-
sion was not a surprising finding. TIMP-1 and -2 gene overexpres-
sion and a synthetic MMP inhibitor mimicked this effect
consistent with previous data for TIMPs in vascular and cancer
cells (DeClerck et al, 1992; Forough et al, 1996; Ahonen et al,
1998; Baker et al, 1998; George et al, 1998). TIMP-3 overexpres-
sion efficiently inhibited invasion of both the moderately invasive
HeLa cell line and the highly invasive HT1080 cells. In other
systems, mouse TIMP-3 overexpression in JB6 murine epithelial
cells failed to inhibit invasion through reconstituted basement
membrane or to affect in vivo tumorigenicity (Sun et al, 1996).
These apparent discrepancies may be due to the differences in
expression levels observed using plasmid- and adenoviral-based
systems or it may represent different sensitivities to phenotypic
alterations induced by TIMP-3 overexpression in tumour cells of
different origins.
TIMP-3 overexpression was associated with induction of apop-
totic cell death of HeLa, HT1080 and MCF-7 cells. This is consis-
tent with our data in vascular smooth muscle cells and melanoma
cells (Ahonen et al, 1998; Baker et al, 1998). Induction of cell
death was associated with an elevation in the number of cells in S
and G2/M phases of the cell cycle determined by BrdU immunos-
taining and flow cytometry. In other systems, the chicken homo-
logue of TIMP-3, ChIMP-3, induced DNA synthesis of
transforming fibroblast cells resulting in detachment of the cells
from the extracellular matrix (Yang and Hawkes, 1992). The
ability of exogenously expressed TIMP-3 to induce DNA
synthesis and apoptosis demonstrates a close link between initia-
tion of cell proliferation and the induction of apoptosis in certain
cell types. The endogenous TIMP-3 promoter has been shown to
be tightly regulated during the G1 phase of the cell cycle with
promoter activity declining prior to S phase entry (Wick et al,
1994). It is therefore feasible that CMV IEP-driven TIMP-3
expression forces cells into the cell cycle. It has also been demon-
strated that TIMP-3 overexpression through generation of stable
colon carcinoma cell lines reduced tumour growth in nude mice
and was associated with cell death by stabilization of tumour
necrosis factor alpha (TNF-a) receptors (Sun et al, 1996; Smith et
al, 1997). Our data here and elsewhere (Baker et al, 1998) indicate
that the TIMP-3-mediated induction of cell death is independent of
MMP inhibitory activity as the effect is not mimicked by BB-94, a
synthetic MMP inhibitor. The physiological involvement of
TIMP-3 in the induction of cell death in the context of in vivo
tumour development remains to be fully determined. High levels
of TIMP-3 have been detected in breast carcinoma (Uría et al,
1994; Byrne et al, 1995) but the role of TIMP-3 in tumour inva-
sion/growth remains to be determined. As high rates of apoptosis
occur within tumour masses, an involvement for TIMP-3 could be
postulated.
Our results have important implications for the role of TIMP-3
in physiological and pathological conditions and also for potential
use of TIMP-3 gene overexpression on cancer gene therapy.
TIMP-3 may have particular advantages over current cell death
strategies as the protein is secreted and remains tightly bound to
the extracellular matrix. This secreted TIMP-3 induces a bystander
effect such that death of uninfected cells can occur. Additionally,
TIMP-3-induced cell death does not require systemic delivery of a
pro-drug, necessary for the thymidine kinase/gancyclovir cell
death strategy. Further development of TIMPs in this context will
clarify the role of MMPs in cancer progression. TIMP-3 appears to
be an attractive candidate for future cancer gene therapy.
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